Comparing Intravenous rhTNK-tPA and Placebo Before Endovascular Thrombectomy for Adults with Large Vessel Occlusion Stroke in an Extended Treatment Window
Led by Xinqiao Hospital of Chongqing · Updated on 2025-12-31
820
Participants Needed
4
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating intravenous recombinant human tenecteplase rhTNK-tPA in adults who have had an acute ischemic stroke caused by a large vessel blockage. This phase III, randomized, double-blind, placebo-controlled trial aims to determine if rhTNK-tPA improves blood flow before thrombectomy and enhances functional recovery at 90 days. The study also monitors whether rhTNK-tPA increases risks such as symptomatic brain bleeding or death.
Participants are randomly assigned to receive either a single intravenous dose of rhTNK-tPA 0.25 mgkg, up to 25 mg or a placebo given over 5 seconds. All participants will undergo endovascular thrombectomy to remove the vessel blockage. Key imaging tests like CT or MRI are done before and 24 hours after treatment to assess brain blood flow and tissue damage.
During the study, patients will have neurological evaluations including stroke severity scales between days 5 and 7, and functional outcome assessments at 90 days. Safety monitoring focuses on bleeding events and mortality during the 90-day period. The trial includes careful review of complications and adverse events, with independent oversight to ensure participant safety and data integrity.
CONDITIONS
Brief Title
Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window
Research Team
Z
Zhongming Qiu, MD
J
Jing Lin, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Pre-existing neurological or psychiatric disorders affecting assessments
Intracranial tumors larger than 3 cm (except small meningiomas)
Intracranial aneurysm or arteriovenous malformation
Terminal illness with life expectancy less than 6 months
Expected inability to complete follow-up assessments
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single day
Participants receive a randomized intravenous injection of either rhTNK-tPA or placebo, followed by endovascular thrombectomy to treat their stroke.
1 treatment visit (in-person)
Follow-up
Duration - 90 days post-treatment
Participants are monitored for safety and recovery, including assessment of functional independence and complications after treatment.
Multiple visits over 90 days
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Global Trial Comparing Intra-arterial Thrombolysis with Tenecteplase or Alteplase Versus No Thrombolysis After Endovascular Thrombectomy for Acute Ischemic Stroke
Study of Early Endovascular Treatment for Acute Ischemic Stroke Caused by Isolated Internal Carotid Artery Occlusion
Study of Mechanical Clot Removal Plus Medical Treatment Versus Medical Treatment Alone for Large Stroke with Big Brain Damage
Studying the Impact of Mechanical Thrombectomy on Patient Outcomes at a Small Stroke Center in Norway
Immediate Angioplasty With or Without Stenting for Acute Ischemic Stroke Caused by Severe Intracranial Artery Narrowing A Multicenter Randomized Trial
Evaluating Low-Dose Intra-Arterial Alteplase After Successful Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion
Study of Adjunct Intra-Arterial Thrombolysis After Successful Reperfusion in Acute Stroke of the Anterior Circulation
A Phase 3 Multicenter Randomized Trial Evaluating Alteplase Treatment Outcomes
Urgent Stenting Versus Continued Endovascular Treatment for Stroke Caused by Intracranial Atherosclerosis in Large Vessel Blockage
An International, Multicenter, Randomized Clinical Trial
Comparing Intravenous rhTNK-tPA and Placebo Before Endovascular Thrombectomy for Adults with Large Vessel Occlusion Stroke in an Extended Treatment Window
Evaluating the Efficacy and Safety of MLC901 NeuroAiD II in Mild to Moderate Ischemic Stroke Patients A Randomized Controlled Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Extending the time window for tenecteplase by effective reperfusion of penumbral tissue in patients with large vessel occlusion: Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 trial.
Vignan Yogendrakumar, Bruce Cv Campbell, Leonid Churilov...